Outcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10)

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The prognosis of acute myeloid leukemia (AML) patients with der(1;7)(q10;p10) who underwent allogeneic hematopoietic stem cell transplantation (allo‐SCT) is unclear due to its rarity. We retrospectively analyzed 151 AML patients with der(1;7)(q10;p10) and compared the findings with those of 853 AML patients with monosomy 7 or chromosome 7q deletion (‐7/del(7q)) using Japanese nationwide registry data. The der(1;7)(q10;p10) group showed significantly better transplant outcomes than the ‐7/del(7q) group. In the multivariate analysis of the der(1;7)(q10;p10) group, additional chromosomal abnormalities and a poor performance status significantly influenced the survival. In conclusion, allo‐SCT is a feasible treatment option for AML patients with der(1;7)(q10;p10).

Related collections

Most cited references 15

Record: found
Abstract: found
Article: found

Is Open Access

Investigation of the freely available easy-to-use software ‘EZR' for medical statistics

Y Kanda (2012)

Although there are many commercially available statistical software packages, only a few implement a competing risk analysis or a proportional hazards regression model with time-dependent covariates, which are necessary in studies on hematopoietic SCT. In addition, most packages are not clinician friendly, as they require that commands be written based on statistical languages. This report describes the statistical software ‘EZR' (Easy R), which is based on R and R commander. EZR enables the application of statistical functions that are frequently used in clinical studies, such as survival analyses, including competing risk analyses and the use of time-dependent covariates, receiver operating characteristics analyses, meta-analyses, sample size calculation and so on, by point-and-click access. EZR is freely available on our website (http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmed.html) and runs on both Windows (Microsoft Corporation, USA) and Mac OS X (Apple, USA). This report provides instructions for the installation and operation of EZR.

0 comments Cited 4001 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Daniel Arber, Attilio Orazi, Robert P. Hasserjian … (2016)

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.

0 comments Cited 2409 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Hartmut Döhner, Elihu Estey, David Grimwade … (2017)

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

0 comments Cited 1769 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Ken Ishiyama:

ORCID: https://orcid.org/0000-0002-6189-0620

ishiyama-knz@umin.ac.jp

Journal

Journal ID (nlm-ta): EJHaem

Journal ID (iso-abbrev): EJHaem

Journal ID (doi): 10.1002/(ISSN)2688-6146

Journal ID (publisher-id): JHA2

Title: EJHaem

Publisher: John Wiley and Sons Inc. (Hoboken )

ISSN (Electronic): 2688-6146

Publication date (Electronic): 06 November 2022

Publication date Collection: February 2023

Volume: 4

Issue: 1 ( doiID: 10.1002/jha2.v4.1 )

Pages: 251-257

Affiliations

[ ¹ ] Department of Hematology Kanazawa University Hospital Kanazawa Japan

[ ² ] Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan

[ ³ ] Department of Hematology Jyoban Hospital of Tokiwa Foundation Fukushima Japan

[ ⁴ ] Division of Hematology Department of Internal Medicine Aichi Medical University Nagakute Japan

[ ⁵ ] Hematology Division Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

[ ⁶ ] Department of Hematology Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital Tokyo Japan

[ ⁷ ] Department of Hematology and Oncology Tokai University School of Medicine Isehara Japan

[ ⁸ ] Department of Hematology Kanagawa Cancer Center Yokohama Japan

[ ⁹ ] Department of Hematology Hiroshima Red Cross Hospital and Atomic‐bomb Survivors Hospital Hiroshima Japan

[ ¹⁰ ] Department of Hematology Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital Nagoya Japan

[ ¹¹ ] Department of Hematology Hyogo Medical University Hospital Hyogo Japan

[ ¹² ] Leukemia Research Center Saiseikai Maebashi Hospital Maebashi Japan

[ ¹³ ] Department of Hematology National Hospital Organization Kumamoto Medical Center Kumamoto Japan

[ ¹⁴ ] Division of Hematology‐Oncology Japanese Red Cross Society Narita Hospital Narita Japan

[ ¹⁵ ] Japanese Data Center for Hematopoietic Cell Transplantation Nagoya Japan

[ ¹⁶ ] Department of Registry Science for Transplant and Cellular Therapy Aichi Medical University School of Medicine Nagakute Japan

[ ¹⁷ ] Department of Hematology and Cell Therapy Aichi Cancer Center Nagoya Japan

Author notes

[*] [* ] Correspondence

Ken Ishiyama, Department of Hematology, Kanazawa University Hospital, 13‐1 Takaramachi, Kanazawa, Ishikawa 920‐8641, Japan.

Email: ishiyama-knz@ 123456umin.ac.jp

Author information

Hiroki Mizumaki https://orcid.org/0000-0002-9933-4638

Ken Ishiyama https://orcid.org/0000-0002-6189-0620

Jinichi Mori https://orcid.org/0000-0002-4255-5616

Article

Publisher ID: JHA2609

DOI: 10.1002/jha2.609

PMC ID: 9928652

SO-VID: 6b18af94-e3c5-4033-9350-1c618b43474d

License:

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

History

Date received : 13 October 2022

Date accepted : 20 October 2022

Page count

Figures: 1, Tables: 1, Pages: 7, Words: 3039

Custom metadata

source-schema-version-number 2.0

cover-date February 2023

details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.5 mode:remove_FC converted:14.02.2023

Keywords: additional chromosomal abnormalities,allogeneic hematopoietic stem cell transplantation,aml,der(1;7)(q10;p10)

Data availability:

Keywords: additional chromosomal abnormalities, allogeneic hematopoietic stem cell transplantation, aml, der(1;7)(q10;p10)

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Most referenced authors 324

See all reference authors

Outcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10)

Read this article at

Abstract

Related collections

Stress signalling in stem cells

Most cited references 15

Investigation of the freely available easy-to-use software ‘EZR' for medical statistics

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Author and article information

Contributors

Journal

Affiliations

Author notes

Author information

Article

History

Page count

Categories

Custom metadata

Comments

Comment on this article

Similar content 1,576

Most referenced authors 324